Bifidobacterium infantis
Useful mainly for adults with IBS (using the 35624 strain) and breastfed-infant microbiome support.
Quick decision guide
May help most
adults with IBS (using the 35624 strain) and breastfed-infant microbiome support
Common dosing range
1 billion CFU/day (35624 strain) for IBS
When to expect effects
Weeks (4–8 for IBS)
Watch out for
effects are strain-specific; caution in severe immunocompromise and very premature infants
What is it
Bifidobacterium infantis (now reclassified as Bifidobacterium longum subsp. infantis) is a probiotic bacterium found in the gut of breastfed infants. It's notable for uniquely digesting human milk oligosaccharides (HMOs) and is used in infant probiotics and adult formulations for IBS.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
irritable bowel syndrome (strain 35624) Good Evidence | Modest but reproducible symptom improvement | adults with IBS using the specific 35624 strain | Weeks |
infant microbiome restoration (breastfed infants) Good Evidence | Marked shift toward Bifidobacterium-dominant microbiome | breastfed infants supplemented with appropriate strains (e.g. EVC001) | Days to weeks |
necrotizing enterocolitis prevention (preterm infants) Limited Evidence | Possible risk reduction | premature infants under medical supervision | During supplementation |
irritable bowel syndrome (strain 35624)
- Effect
- Modest but reproducible symptom improvement
- Best fit
- adults with IBS using the specific 35624 strain
- Time
- Weeks
infant microbiome restoration (breastfed infants)
- Effect
- Marked shift toward Bifidobacterium-dominant microbiome
- Best fit
- breastfed infants supplemented with appropriate strains (e.g. EVC001)
- Time
- Days to weeks
necrotizing enterocolitis prevention (preterm infants)
- Effect
- Possible risk reduction
- Best fit
- premature infants under medical supervision
- Time
- During supplementation
Evidence for 3 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
irritable bowel syndrome (strain 35624)
Disease adjunctThe B. infantis 35624 strain has been studied in multiple trials showing modest but reproducible improvements in IBS symptoms such as abdominal pain, bloating, and bowel difficulty over 4–8 weeks. The effect is strain-specific and does not generalize to all B. infantis products.
Bottom line: A reasonable, strain-specific option for modestly reducing IBS symptoms.
infant microbiome restoration (breastfed infants)
Biomarker supportB. infantis uniquely metabolizes human milk oligosaccharides, and supplementation in breastfed infants reliably increases Bifidobacterium dominance and short-chain fatty acid production. This is primarily a measured microbiome/biomarker change; longer-term clinical outcomes are still being studied.
Bottom line: Reliably shifts the breastfed-infant microbiome toward a Bifidobacterium-dominant pattern.
necrotizing enterocolitis prevention (preterm infants)
Disease adjunctProbiotic supplementation including B. infantis has been studied for reducing necrotizing enterocolitis risk and improving feeding tolerance in preterm infants. Evidence is preliminary and strain-dependent, and probiotic use in very premature infants requires medical guidance.
Bottom line: Preliminary, supervised evidence for reducing NEC risk in preterm infants.
How it works
How to take it
What to track
3 commercial forms
Compare the main delivery options and what they’re best suited for.
Align (B. infantis 35624)
1 billion CFU/day for IBS.
Most studied adult IBS strain.
EVC001 (Evivo)
Designed for breastfed infants.
Infant strain optimized for HMO digestion.
Multi-strain infant probiotics
Various pediatric products.
Often combined with other Bifidobacteria.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
rare bacteremia in severely immunocompromised individuals and very premature infants
Who should avoid it
- severely immunocompromised individuals without physician input
- extremely premature infants without medical guidance
Pregnancy & breastfeeding
Generally considered safe; use products as directed and consult a clinician if immunocompromised.
Interactions
may kill the live bacteria; separate dosing
theoretical caution with live organisms in immunosuppression
Choosing a product
What to look for on the label — and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Will any B. infantis probiotic help my IBS?⌄
Effects are strain-specific. B. infantis 35624 (Bifantis, in Align) is the strain with the most clinical evidence. Generic 'B. infantis' may not produce the same effects.
Should I give B. infantis to my breastfed baby?⌄
Modern infants often lack B. infantis even when breastfed (due to antibiotic exposure, C-section delivery, etc.). EVC001 supplementation has emerging evidence for restoring it. Discuss with your pediatrician.
Why is B. infantis special?⌄
It's the only species known to fully digest the complex sugars (HMOs) in human breast milk. This allows it to thrive in the infant gut where other bacteria cannot.
References by claim
irritable bowel syndrome (strain 35624)
infant microbiome restoration (breastfed infants)
Track Bifidobacterium infantis with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.